Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials.

5595Background: Immune checkpoint inhibitors have shown promising activity in multiple tumor types. However, there are no approved IO for GYN. Methods: We identified GYN pts treated with IO from 20...